Results: Compared with controls, patients with schizo phrenia showed greater GM volume loss in the frontal lobe during the 2-year follow-up (left: -3.3 vs -0.6 cm 3 , P=.004; right: -3.7 vs -0.8 cm 3 , P= .005) and leftfrontal CSF volume increase (left: 6.7 vs 2.4 cm 3 , P= .006), In addition to frontal volume, changes for total GM (-37.1 vs -14.5 cm\ P= .00l) and left parietal GM vs -2.2 cm), P=.04) were significantly different in schizo phrenic patients compared with controls. No signifi cant differences emerged for patients with bipolar dis ease. Greater left frontal GM volume loss was related to more weeks of hospitalization, whereas severity of nega tive symptoms correlated with CSF increase in patients v,rith schizophrenia,
Conclusions:
Patients with schizophrenia or other psy choses showed greater loss of GM volume and increase of CSF in the frontal lobe relative to controls. Progres sive changes were more evident in patients with schizo phrenia than those with bipolar disorder. These changes in specific brain volumes after onset of psychotic symp toms may be related to markers of poorer prognosis.
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Author Affiliations are listed at the end of this article. P ROGRESSIVE B~<\IN CHANGES have been found in adults with schizophrenia during the initial years after a first psychotic episode.! These progressive brain changes have been as sociated with poorer ou tcome, al though not all studies have reported such a relationship.7 A progressive loss of cor tical gray matter (GM) volume and an ab normal increase in venn'icular volume have also been described in studies 81l of ado lescent patients with childhood-onset scbizophrenia (COS) with a long dura tion of illness conducted by the National Institute of Mental Health. Cortical GM loss in COS patients recruited at the Na tional Institu te of Mental Health appears to start in the parietal lobe, subsequently spreading through the temporal, frontal, and prefrontal cortices. 12 ,13 Early-onset psychosis (EOP), defined as psychotic symptoms within a psychi atric disorder appearing before the age of 18 years, has been shown to be a marker of poor prognosis.14,15 Patients with EOP may eventually develop schizophrenia, bipolar disorder, or other psycboses.1 6 Al though some studies l7 , 18 of COS have re vealed no progressive changes during a 2 to 3-year period in prefrontal GM deficit or in the ventricular enlargement ob served relative to control subjects, few longitudinal studies!7,!9-22 and even fewer research teams have investigated the struc tural brain changes that occur in tbe ado-1escent brain during the first few years after onset of a first psychotic episode, and the results have not been con sistent. Different severity, diagnoses, age at onset, and duration of illness may have contributed to the incon sistent results in previous studies. It is unclear whether EOP patients other than those with schizophrenia show progressive brain changes during the first few years af ter symptom onset. A 2VI-year brain imaging follow-up study comparing healthy controls and patients \\lith psy chosis not otherwise specified and COS found the great est reduction of GM volumes in the COS group, suggest ing that cortical volume loss was more evident in COS when compared with other childhood-onset psycho ses.
B In another longitudinal study by the same group, 9 children with bipolar 1 disorder were compared with 8 children with atypical psychosis and a matched healthy control group; the brain trajectories showed a similar pat tern (cortical GM gain in the left temporal cortex and bi lateral GM reduction in the anterior and subgenual cin cortex) in both patient groupS.23 Finally, male EOP patients (mean age, 15.8 years) showed progressive GM volume loss and CSF volume increase in the frontal lobes, regardless of a follow-up diagnosis of schizophrenia or nonschizophrenia psychotic disorder. 22 The Child and Adolescent First-Episode Psychosis Study is a multicenter follow-up study that aims to assess clinical characteristics, prognostic factors, diagnos tic specificities, and pathophysiologic changes in the brain during the first 2 years after a first psychotic episode through an integrative and translational approach.24 Our sample includes a matched comparison group composed of healthy children and adolescents from each participat jng center to control for potential demographic factors kno'wn to affect neurodevelopment. We report here on one of the primary aims of the study-the comparison of structural brain changes between patients with first episode EOP and healthy controls during a 2-year pe riod. Patients were classified into schizophrenia, bipolar disorder, and other psychoses diagnostic groups based on a 2-year follow-up clinical assessment. Thereafter, we as sessed whether diagnostic subgroups differed with re spect to longitudinal brain changes. We also examined the relationship of brain changes \\lith clinical prognostic vari ables and antipsychotic exposure.
. On the basis of our preliminary results and the ous literature on adults, our initial hypotheses were that (1) patient.s would show grea ter progressive brain changes than those seen in healthy controls, mainly in the frontal lobe, (2) progressive changes would be greater in pa tients who develop schizophrenia, and (3) greater pro gressive changes would be markers of poorer prognosis.
STUDY PARTICIPANTS
The complete methods of the CAFEPS, a multicenter, tudinal follow-up study of first-episode psychosis in children and adolescents, have been comprehensively described else where. 24 A sample of 110 patients and 98 healthy controls matched for age, sex, and parental socioeconomic status was consecutively recruited in outpatient and inpatient units in 6 hospitals in Spain. Recruitment took place between March 1, 2003, and November 31,2005 . Inclusion criteria were age be tween 7 and 17 years with a first episode of psychosis of less than 6 months' duration at baseline assessment. The exclu sion criteria were (1) concomitant Axis I disorder at the time of evaluation, (2) mental retardation according to DSM-IV cri teria, (3) any neurologic or pervasive developmental disorder, (4) history of head trauma with loss of consciousness, (5) preg nancy, and (6) substance abuse or dependence but not use if psychotic symptoms persisted 14 days after a negative urine drug test result. The intention was to recruit an equal number of patients and healthy controls at each of the participating clini cal centers to ensure the homogeneity of sociodemographic fac tors. The study was approved by all institutional review boards at each clinical center, and written informed consent was ob tained from all participants and/or their parents or legal guard ians. All controls and patients met magnetic resonance imaging (MRI) safety criteria.
Of the total C\FEPS sample, 92 patients and 94 healthy con trols underwent MRI at baseline. Baseline differences in vol ume measurements have been reported for the whole sample elsewhere 26 A subsample of 61 first-episode psychosis pa tients (21 girls) and 70 healthy controls (23 girls) completed both the baseline and 2-year follow-up MRI and correspond ing clinical evaluations. The MRI attrition was due to loss to follow-up in 11. 9% (of the total baseline refusal to parin 7.0%, technical problems in fear of the MRI in orthodontics in 1.6%, change of residence in 1.6%, and other in 0.5%. Only those patients and healthy controls who underwent the MRI and clinical assessments both at baseline and at the 2-year follow-up visit were included in the analy ses. This approach allowed us to longitudinally examine brain changes in the same sample over time.
CLINICAL AND FUNCTIONAL ASSESSMENTS
Diagnosis was established according to DSM-IV criteria using the Spanish version of the Kiddie-Schedule for Affective Dis orders and Schizophrenia, Present and Lifetime Version, a semi structured diagnostic interview designed to assess current and past psychopathologic conditionsy, 28 The interview was ad ministered to both patients and healthy controls at baseline and follow-up. Parents, patients, and healthy controls were inter viewed by psychiatrists or clinical psychologists use of the instrument in children and adoles cents.
consensus was achieved for those patients in whom the presence or absence of a psychiatric disorder was in doubt. For data categorization, we used the final diagnosis es tablished at the 2-year clinical follow-up assessment. Three main diagnostic categories were established: schizophrenia, bipolar disorder, and other According to the diagnosis at the 2-year assessment, our patient sample inc1udeq,.25pa tients vvithschizophrenia, 16 vvith bipolar disorder, and 20 'o/iih~, . . other psychoses (including schizoaffective disorder in II, de-~' ,1 pression with psychotic features in 3, brief psychotic disorder' in 1, and psychOSiS not otherwise specified in 5).
Clinical and functional assessments were performed at the , corresponding clinical center by trained psychiatrists at differ ent times. The rater was the same for each patient at baseline and 2-year follow-up.
of "ymptoms was measured using the Spanish validated version of the Positive and Negative Syn drome Scale (PANSS),
Interrater reliability for the PANSS was determined using dle intraclass correlation coefficient, which was superior to 0.80 for all subscales and total score. Longitu dinal change in all P ANSS subscales and P ANSS total score was estimated as measures at follow-up minus measures at base line. The mean baseline and follow-up PANSS scores were also examined to capture traitlike individual differences in the se-ARCH GEN PSYCHIATRY/VOL 69 (NO 1), JAN 2012 WWWARCHGENPSYCHIATRY.COM verity of the patients' clinical trajectories. Severity of disability and level of functioning in patients were determined using the Children's Global Assessment of Functioning (C-GAF) scale. This scale rates the level of functioning in the past month on an ordinal scale ranging from 1 (requires supervision at all times) to 100 (high functioning). The physician completed this scale after the entire assessment visit with the patient was finished, based on his/her own clinical judgment and information given by the patient and hislher parents or legal guardians. Longitu dinal change in C-GAF scores was estimated as the C-GAF score at follow-up minus the C-GAF score at baseline. In keeping with previous reports,5 the other variable used to assess prognosis was the number of weeks hospitalized during the 2-year follow up. Premorbid social adjustment was assessed using the Pre morbid Adjustment Scale (PAS). 32 We used the PAS-I for so ciability and withdrawal where 5-item scores were obtained in each life period (childhood, early adolescence, and late ado lescence), rating only those life periods considered to be pre morbid with regard to age of illness onset. This study about compatibility among the scanners suggested that pooling of multisite data adds small error for whole brain measurements and an intersite coefficient of variation ranging from 1.8% to 5.2%, respectively, for GM and cerebrospinal fluid (CSF) 36 However, volume estimations of white matter (WM) were more prone to site-related errors than GM or CSF. On the other hand, measurement error of the occipital lobe was high, with the intersite coefficient of variation reaching 11.7% for VI."M and 17.3% for CSF.36 On the basis of these findings, regional measurements of WlYl and of the occipital lobe were discarded for this study.
Segmentation and Region of Interest Definition
The MRls were processed using software developed in house incorporating a variety of image processing and quantification tools.
36 .
37 Total GM and CSF volumes in the frontal, parietal, and temporal lobes were obtained using a method for semiau tomated segmentation of the brain based on the Talairach pro portional grid system. The method follows a 2-step proce dure 37 First, an initial segmentation of cerebral tissues into GM. WY1, and CSF using SPM2 (Statistical Parametric Mapping, Well come Institute; http://www.filjon.ucLac.uk/spm) routines for multi modal (Tl and T2) segmentation was performed. The SP:tv: algorithm for tissue segmentation includes a method for elimi· nating the effect of radio frequency field inhomogeneities 40 Mul· timodal segmentation was proven to be more robust than the Single modality in a multicenter setup.36 Second, a Talairacl: grid was built on each edited brain MRI by manually selectinf the position of the anterior and posterior commissures and es tablishing a third point position in the midsagittal plane. The coordinates of these points were used to calculate the trans formation (rigid rotation) required to comply with the Ta lairach orientation (ie, setting the anterior commissure posterior commissure line in the axial horizontal plane and the interhemispheric plane in the vertical orientation).41 Our soft· ware application automatically finds the outer brain limits iI: Talairach orientation, and3-dimensional Talairachgrids are buil: for each brain. The Talairach grid represents a piecewise lin· ear transformation and a tessellation of the brain into a 3-di mensional grid of 1056 cells representing homologous brait regions across study participants. 41 The region of interest (ROJ measurements were obtained by superimposing 3-dimen· sional tissue masks corresponding to GM, WM, and CSF onte each participant's Talairach grid, where the ROls were definee as sets of Talairach grid cells. 36 ,38,39 Volume for each tissue typt was measured by adding up the data from the Talairach grk cells associated with each ROIY
The validity of the Talairach-based procedure as an auto· mated segmentation and quantification tool suitable for volu metric studies has been proven,3S.39 and the tool has been usee in other longitudinal studies.
2 In our implementation, all manua procedures were performed by a single operator blinded to the diagnosis and origin of each MRI, thus avoiding any potentia: bias or interrater variability. A detailed report about the reli ability of our implementation in this multicenter setup is pro· vided elsewhere 36 
Regions of Interest
The ROls included in the analysis were the frontal, parietal, ane temporal lobes, defined using the boundaries previously de scribed for the Talairach method. 38 Whole brain \hiM, GM, ane CSF volumes were also measured. These ROls were chosen be· cause prior literature has shown that these regions are most likely to present volume changes over time in adolescent patients 'Nit~. first-episode psychosis. 36 Volumes were obtained for each RO: in both hemispheres.
Multicenter reprodUCibility of measurements was mud higher for GM than for WM. 35 For this reason, volume data fa: WM was only included for total WM and not for the differen: brain lobes, thus reducing the dimensionality of the analysis Intracranial volume (ICV) was obtained by adding the total GM WM, and CSF volumes, including the cerebellum.
Measurement of Longitudinal Changes
Longitudinal change in volume was measured as the difference between the volume of each ROI at baseline and follow-up (ie volume change =follow-up volume baseline volume).
STATISTICAL ANALYSIS
Normality of the distributions and homoscedasticity of vari ance among groups were checked before the analyses. To tes:
ARCH GEN PSYCHIATRY/VOL 69 (NO. 1), JAN 2012 WVvW.ARCHGDIPSYCHIATRY.COM for differences in demographic data between patient sub groups and controls, analysis of valiance, Fisher exact, or X2 tests were used, depending on the type of variable. A comparative analysis of volumetric differences at base line between patients and controls has been reported else where 26 To test for longitudinal changes in clinical symptom scores and volume variables within patient and control groups, paired t tests were used. To test for longitudinal changes in vol ume variables among the 3 diagnostic subgroups and con trols, an analysis of covariance (ANCOVA) model was used. This model included age, ICV at the first scan, interscan inter val, interscan ICV change, and site as covariates of no interest. These 5 covariates were included in the model because of their potential effect on volume data, despite showing no signifi cant differences among the groups. Assuming that ICV should not change over time, interscan Ie\! change (lCV2 ICVl) was included in the ANCOVA to remove a potential effect of spu rious method variance associated 'I'I'ith change from ICVI to ICV2. The assumption of no interaction between each of the covariates and the group factor was checked for all variables. The analysis was performed using within-subject longitudinal volume change (follow-up baseline) as the dependent vari able. When this variable showed a main effect, post-hoc Sidak tests were used to detect the pair of groups showing signifi cant differences. This analysis was preferred over repeated measures ANCOVA of raw data at baseline and at follow-up because the confounding effect of scanner site was minimized by using the within-subject change values. The analysis of lon gitudinal changes was performed using the pooled sample of boys and girls. The initial full-factorial model was tested, in cluding sex and group X sex interaction. However, because no significant effects of sex or the interaction term were signifi cant, sex was not included in the final model. (Results of this analysis are available on request.)
To examine the association between volumetric measure ments with cumulative dose of antipsychotic medication and clinical and functional outcome scores, such as longitudinal dif ferences in C-GAF, number ofweeks hospitalized during follow up, IQ, and premorbid social adjustment (as measured by the PAS), Pearson linear correlation coefficient was used. All sta tistical analyses were performed using SAS statistical soft ware, version 9 .0 (SAS Institute, Inc), and a 2-tailed P < .05 was considered statistically significant. \Ve chose not to ad just P values to avoid type I errors due to multiple compari sons because the main goal of the study was to describe lon gitudinal brain changes across groups rather than drawing inferences abo1:1t group membership based on the differences observed in morphometric data.
RESULTS

SOClODEMOGRAPHIC AND CLINICAL CHARACTERISTICS
Patients and controls were not significantly different in terms of age, sex, parental socioeconomic status, years of education, race, handedness, or between-scan fol low-up period (Table I) . Mean (SD) duration of ill ness for the group of patients, defined as the time be tween the onset of the first positive symptom and baseline MRI, was 3.3 (2.7) months (range, 1-12 months). Mean (SD) duration of antipsychotiC treatment at baseline was 9.9(11.2) weeks (range, 0-16 weeks) for the pooled group of patients. The mean (SD) daily antipsychotic dose at baseline was 270.5 (148.3) mg in chlorpromazine equiva lents. 34 ,35 Of the final sample included, 41.0% of pa tients had schizophrenia, 26.2% had bipolar disorder, and 33.8% had other psychoses at the 2-year follow-up. The patient subgroups did not differ in duration of illness or duration of antipsychotic treatment at the time of MRI but differed in age, which was therefore included as co variate for comparative analyses (Table 1) . Mean (SD) cumulative antipsychotic dose during the 2-year follow-up was 168 840 (213 209) mg in chlor promazine equivalents. 34 .
35 With regard to clinical mea surements, all PANSS scores decreased during the 2-year follow-up ( Table 2) .
No differences were found between the patients in the general CAFEPS sample who had both the baseline and 2-year follow-up MRI assessments (n=61) and those who did not (no baseline and/or follow-up MRI; 18 had no MRI at baseline, 26 had no MRI at the 2-year follow-up, and 5 patients had no MRI either at baseline or follow-up) with regard to age, sex, or clinical or functional characteristics at baseline. The only variable that significantly differed be tween the 2 groups was estimated IQ Cfable 2).
DIFFERENCES BETWEEN PATIENT SUBGROUPS AND HEALTHY CONTROLS
Using the same ANCOVA model to test for overall be tween-group differences, post-hoc Sidak tests revealed that schizophrenic patients had significantly greater (Sidak P< .01) losses of whole brain GM and greater (Sidak P < .05) increases ofleft frontal CSF volumes relative to healthy controls (Table 3) . Schizophrenic patients also had greater losses of GM volume in the frontal lobe (right: Sidak P< .05; left: Sidak P< .01) and in the left parietal lobe (Sidak P< .05) compared with healthy controls (Table 3 ). The other ~choses group also showed losses in whole brain GM vomme'"ZSidak P< .001) relative to healthy controls (Table 3 ). These patients also had a sig nificantly greater (Sidak P < .05) loss of GM in the fron tal bilaterally and left parietal (Sidak P< .01) lobes, as well as greater increases in CSF volume in the frontal lobes (left Sidak P< .001; right: Sidak P< .05) relative to con trols (Table 3) . Bipolar disorder patients showed no sig nificant differences in longitudinal volume change rela tive to healthy controls, although all the differences were in the same direction as other patient subgroups (Table 3 and eTable; http://www.archgenpsychiatry.com). The AN COY A model among the 3 diagnostic subgroups re vealed no significant differences (data not shown). This was still true when weeks of hospitalization or cumula tive dose of treatment were included in the model as co variates (data not shown).
ASSOCIATION BETWEEN VOLUME CHANGES AND CLINICAL AND OUTCOME VARIABLES Abbreviations: C-GAF, Children's Global Assessment of Functioning; MRI, magnetic resonance imaging; PANGS, Positive and Negative Syndrome Scale.
aAnalysis of variance was used for comparisons between quantitative measures, and x 2 or Fisher exact test was used for comparisons between qualitative measures bparental socioeconomic status assessed with the Hollingshead Scale 42 (ranging from 1 to 5). Arating of 5 corresponds to the highest socioeconomic status and a rating of 1 to the lowest, CPatients were polymedicated, increasing the sample size for medication. At baseline, 4 patients with schizophrenia were taking 2 antipsychotics and 3 patients with bipolar disorder were taking 2 antipsychotics. whereas only 1 patient from the other psychoses group was taking 2 antipsychotics and 1from this group was taking 3 antipsychotics. At the 2·year follow-up, 1 patient with schizophrenia, 2 patients with bipolar disorder, and 3 patients from the others subgroup were taking 2 antipsychotics, whereas 1 bipolar patient was taking 3antipsychotics.
dOther indicates antidepressants or anxiolytics. No patient was treated with lithium in this sample.
There was also a significant association between left fronand left parietal CSF change 0. 45 . aNoncompleters are patients lor whom we do not have a baseline or follow-up magnetic resonance imaging data or from whom the data were not good enough to be used for the study. Comparison of symptom severity and other sociodemographic factors and predictors of functional outcome for these patients and completers was performed at baseline.
bAbsolute change (follow-up minus baseline) in symptom severity is presented for com pieters.
"Student t test comparative analysis between completers and noncompleters at baseline. P= .02) PANSS change scores and left parietal CSF loss in the other psychoses subgroup, suggesting that de crease in CSF yolume is associated with less improve ment on total score and the presence of positive psy chotic symptoms during the 2-year follow-up.
In this longitudinal study, patients who ended up with a diagnosis of schizophrenia showed greater progressive brain changes than healthy controls in the 2-year fol low-up period after the first psychotic episode. In the pa tients with schizophrenia, progressive volume changes in certain brain areas were related to markers of poorer prognosis, such as more weeks of hospitalization dur ing follow-up and less improvement in negative symp toms and PANSS total score. Bipolar disorder patients did not show any Significant difference when compared with healthy controls. In the control group, longitudinal brain changes were consistent with the expected pattern de scribed for healthy adolescents. 43 . 45 Some cross-sectional studies
-
4B have compared pa tients with bipolar disorder and schizophrenia in terms of cortical brain volume differences, with most of them show ing larger reductions in the schizophrenia group. Along the same lines, a meta-analysis including studies with schizophrenic patients and studies with bipolar patients has shown that GM reductions in the schizophrenia stud. ies are more extensive, especially in neocortical struc tures. 49 To the best of our knowledge, only one previous study22 with a smaller sample size (n= 16) has assessed whether progressive brain change.,> are diagnosis speCific. In that previous study, first-episode male patients who ended up with a diagnOSiS of schizophrenia (and not of bipolar disorder) showed significant frontal GM reduc tions compared 'with healthy controls. We have now rep licated this finding in a larger and independent sample. Our results do not support diagnOSis-specific trajectories of brain volume changes in the first 2 years after illness onset because there were no significant differences in vol ume loss between the diagnostic subgroups. However, the schizophrenia and the other psychoses groups show dif ferent trajectories from healthy controls, whereas the bi polar disorder group does not. Patient subgroups did not differ in sOciodemographic variables, duration of illness, or antipsychotic exposure with the exception of older age at the time of the MRI (schizophrenia, 15.5 years; bipolar disorder, 16.6 years). Although age was included as a co variate in the comparative analYSiS, this does not fully con- trol for these variables if the trajectories are age depen time of assessment, 163 years) who showed a progre dent In addition, data from the other psychoses group sive decrease in frontal-parietal growth rates in the It should be interpreted with caution because this group is hemisphere during 5 years of follow-up. 52 We report pI a heterogeneous group in which some of the patients may gressive brain changes during adolescence, \vith great, end up developing schizophrenia or bipolar disorder in loss of frontal GM volume in patients compared with co: the long run. We have shown that, contrary to the troIs in an EOP cohort with a mean age of approximate: nostic stability found in first-episode patients vvith schizo IS years at onset. All these results suggest a continuu: phrenia and bipolar diagnoses at these ages, the stability between early-onset and adult-onset psychotic disorder of the other psychoses group is IOW. 16 Compared with most published studies, our samp·. Progressive reduction in frontal GM volume and in has a very short duration of illness before baseline 3: crease in frontal CSF volume have been reported during sessment.ln fact most of the previous studies 13 ,53 in earl' the initial years after the onset of schizophrenia in young onset schizophrenia or early-onset psychoses are not wit adults 1 ,2.5o and later in the illness. s1 This has also been re first-episode patients because patients included in tho~ ported in very early-onset schizophrenia (mean age at the studies are usually referred to the participating ins tin tions for refractoriness after some years in treatment. Con sidering this short duration of illness at the baseline MRI (mean,3.3 months) and short time of exposure to anti psychotics (mean,9.9 weeks) in our sample, the base line structural changes might seem to have occurred be fore the onset of the positive symptoms. However, based on our data, we cannot determine when frontal lobe changes first occurred. The smaller volume in patients at baseline, shortly after the onset of the first positive symptoms, may reflect a disruption of developmental pro cesses taking place before the appearance of the first psy chotic symptoms (eg, neuronal migration 54 or synaptic pruning 55 . 56 ). Although the progressive decrease in fron tal GM and the increase in frontal CSF in our sample might be interpreted as a consequence of the toxic effect of psy chosis on brain structures, perhaps through an indirect mechanism such as increased cortisol produced by in creased stress,57 some researchers have argued against ex planations based solely on volume differences in the ab sence of concurrent and consistent evidence of neuronal death and acceleration of clinical progression. 58 ,59 As an alternative, structural brain disease in patients with psy chosis may be due to disrupted neurodevelopmental mechanisms starting after illness onset (eg, impaired syn aptic plasticity58) and continuing during the first few years of illness. In any case, brain maturation continues until early adulthood, and any event occurring before comple tion of maturation, such as the progressive brain changes that we observe in this study, could be conceptualized as neurodevelopmental in nature. Progressive prefrontal volume loss has been reported in adolescents with bipolar disorder 60 The former study did not include a schizophrenia comparison group, and participants had a wider age range than ours 00-21 years for bipolar disorder patients and 11-19 for healthy con trols). Use of imaging techniques such as voxel-based mor phometry48 could help delineate GM volume differ ences more speCifically among diagnostic groupS. 12, 60 Some of the progreSSive brain changes could be sec-l ondary to antipsychotic exposure, although there were ARCH GEN PSYCHIATRY/vOL 69 (N O. 1), JAN 2012 WWW.ARCHGENPSYCHIATRY COM 23 among the 3 diagnostic subgroups during the 2 years of follow-up that couLd explain the larger brain changes seen in the schizophrenia subgroup compared with the healthy controls. Because previous studies 61 with nonhuman pri mates show a reduction in brain volume after exposure to antipsychotics and because antipsychotic exposure was found to be related to smaller GM volumes and larger decreased \-VM volume in a recent longitudinal study62 of patients with first-episode schizophrenia, the role of antipsychotics in progressive brain changes in humans should be addressed in future studies. Almost all pa tients in this cohort were treated with second-gener ati.on antipsychotics. Therefore, our results do not seem to support previous suggestions that second-generation antipsychotics may counteract progressive deteriorative effects by enhancing synaptic plasticity and celluLar re silience, or at least if they do so, they do not completely prevent excess volume loss. 1,63 ThL<; was a naturalistic study; we therefore cannot compare the effect offirst-and second generation antipsychotics on brain volume changes be -'-cause we did not have a group of patients treated only with first-generation antipsychotics. The underlying mechanisms of brain volume changes in schizophrenia and other psychotic disorders are not yet understood. Previous longitudinal studies in adult schizo phrenia patients have correlated brain volume changes ,vith duration of untreated psychosis,64 poorer function at follow Up,4,6 number of hospitalizations,s,:;] hospitalization time,65 and worsening of neuropsychological performance,66-68 The relationship with symptoms is more controversial, with some studies showing a direct inverse relationship be tween brain volume changes and symptom changes at fol low-up and some studies not showing any such relation ship (for a review, see the article by Hulshoff Pol and KahnI). In the present study, we showed a correla tion be tween different GM volume changes and changes in symp toms as measured by PANSS. In all cases the relationship was in the expected direction, with less improvement re lated to larger losses of GM volumes. There are few stud ies of clinical correlates of progressive changes in pediat ric psychosis popuLations. Ventricular enlargement at2-year follow-up has been related to higher scores on the Brief Psychiatric Rating Scale at follow-up in COS. 9 Higher rates of GM volume loss in the frontal cortex have been corre lated with more severe negative symptoms and faster tem poralloss with greater severity of positive symptoms in COS. n On the contrary, greater GM volume reduction in COS has been related to greater clinical symptom im provement at follow-up.ll The relationship between im provement in symptoms and greater GM reduction in the former study was unexpected and did not seem to de pend on the type of medication or severity of symptoms at baseline or follow-up. One speculative reason sug gested by the authors for this finding was the existence of compensatory synaptic and cellular pruning of malfunc tioning neurons.
Some of the limitations of the present study include the mllowing. First, our analysis protocol is restricted to brain lobes, which limits findings to large-scale brain changes. Sttond, the smaller sample sizes when the patients are sub divided into different diagnostic groups may be respon sible for type II errors lack of significant differences between bipolar disorder patients and healtbycontrols or lack of significant differences among the 3 diagnostic sub groups). Third, all patients \\ith bipolardison:lerhad psy chotic SYlllptoms, usually\\ith a first manic episode, which suggests that our group of bipolar patients is probably bi ased toward a severe group. Fourth. adjusIingPvalues to avoid type I erro IS due to multiple comparisons might have eliminated some of the differences we ob5erved. How ever, we have provided the P values obtaior.d to allow the reader assessment of this limitation.. Doe ofthe strengths of the study is the short duration of iIIness;md short an tipsychotic treatment before the first.\IRI ;md the homo geneity of sociodemographic factors in the paimland con trol samples. The length of the follow-up pr:riod was also carefully set the same for all participants. Ihus reducing the effect of other possible confounding £.:tors on the analysis of longitudinal changes.
In 
